Atara Biotherapeutics | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf...
Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company leverages the unique biology of EBV T cells to create a robust pipeline of T-cell immunotherapies, including treatments for Epstein-Barr virus positive post-transplant lymphoproliferative disease and multiple sclerosis.
Website
Headquarters
Thousand Oaks, CA
Size
201-500 employees
Industry
Biotechnology Research
Specialities
biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, progressive multiple sclerosis
🛍️ Atara Biotherapeutics Product and Pricing News →
👔 Atara Biotherapeutics CEO, Management and Leadership Team →
⚔️ Atara Biotherapeutics Alternatives and Competitors →
💼 Atara Biotherapeutics Hiring and Layoffs →
🤖 Atara Biotherapeutics Developer, Integration and Automation News →
📈 Atara Biotherapeutics Financials, Fundraising and Valuation News →
🛍️ Atara Biotherapeutics Product and Pricing News
- Atara Biotherapeutics is mentioned among key players in the growing TIL Cell Therapy Market projected to reach USD 4.15 billion by 2033.
👔 Atara Biotherapeutics CEO, Management and Leadership Team
-
President and CEO
[email protected] -
Chief Operating Officer and Chief Financial Officer[email protected]
-
Chief Executive Officer[email protected]
⚔️ Atara Biotherapeutics Alternatives and Competitors
- Tizona Therapeutics |
- Synergy Pharmaceuticals |
- NGM Bio |
- MacroGenics |
- UroGen Pharma |
- Organigram |
- Lyell |
- Moderna |
- Jazz Pharmaceuticals |
- BeiGene |
- Agenus |
- Puma Biotechnology |
- Kojin |
- Cero Therapeutics |
- Verismo Therapeutics |
- Tmunity Therapeutics |
- Alector |
- Fate Therapeutics |
- Sutro Biopharma |
- Caribou Biosciences |
- Immunocore Holdings
💼 Atara Biotherapeutics Hiring and Layoffs
- Zhongde (Ken) Wang Ph.D has left Atara Biotherapeutics, where he served as Director in Viral Vector Development, Process Science in the United States, to join Blue Lake Biotechnology as Senior Director of Process Development.
- Sergio Arce, M.D., Ph.D. has left Atara Biotherapeutics as Medical Director, Clinical Sciences to join Nkarta, Inc. as Medical Director in the United States.
- Ajay Malik is leaving Atara Biotherapeutics as Director, Medical Writing to join Harmony Biosciences as Director, Medical Writing in the United States.
🤖 Atara Biotherapeutics Developer, Integration and Automation News
📈 Atara Biotherapeutics Financials, Fundraising and Valuation News
- Atara Biotherapeutics has 70.9% institutional ownership and a beta of 0.32, indicating strong investor confidence and lower volatility compared to Creative Medical Technology.
People also viewed
- Tune Therapeutics |
- Kapadi |
- 2seventy bio |
- Ridecell |
- MOQO |
- Joyride |
- Urban Sharing |
- Eccocar
